Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2024 04:13 ET | Source: Curium US LLC

핵의학 기업 Curium, Eczacibaşi-Monrol 인수 통해 Lutetium-177 생산능력 강화와 PET 입지 확대 전망

Eczacıbaşı-Monrol 인수 제안에 대한 내용은 다음과 같다: 이미 진행되고 있는 기존의 Lu-177 파트너십에 기반해 동위원소 제조분야의 선도적인 기업을 구축한다.현재 Curium이 진출하지 않은 지역을 대상으로 12개의 PET 사이트를 Curum의 기존 네트워크에 포함시킨다.Curium은 SPECT 제조 역량과 광범위한 물류 인프라를 추가로...
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium 计划通过收购 Eczacibaşi-Monrol 的协议大幅扩大镥-177 产能及 PET 业务范围

此项拟议的 Eczacıbaşı-Monrol 收购将：在现有的镥-177 合作伙伴关系基础上，创立领先的同位素制造商在 Curium 目前没有业务的地区为其现有网络增加 12 个 PET 站点为 Curium 增加 SPECT 生产能力和广泛的物流基础设施提高诊断和治疗方案的可靠性，从而造福患者巴黎, April 09, 2024 (GLOBE NEWSWIRE) --...
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium วางแผนที่จะขยายกำลังการผลิตลูทีเชียม-177 และพื้นที่ครอบคลุมในการให้บริการ Pet อย่างมีนัยสำคัญ ด้วยข้อตกลงที่จะเข้าซื้อกิจการ Eczacibaşi-Monrol

การเข้าซื้อกิจการ Eczacıbaşı-Monrol ที่เสนอจะ: ต่อยอดความร่วมมือที่มีอยู่ใน Lu-177 เพื่อสร้างผู้ผลิตไอโซโทปชั้นนำเพิ่มสถานที่ปฏิบัติงาน PET 12 แห่งไปยังเครือข่ายที่มีอยู่ของ Curium...
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium Rancang Kembangkan Kapasiti Lutetium-177 dengan ketara dan Jejak Pet dengan persetujuan untuk memperoleh Eczacibaşi-Monrol

Cadangan pengambilalihan Eczacıbaşı-Monrol akan: Membina perkongsian sedia ada dalam Lu-177 mewujudkan pengeluar isotop terkemukaTambah 12 tapak PET pada rangkaian sedia ada Curium di geografi yang...
April 09, 2024 04:13 ET | Source: Curium

Curium plant mit der Vereinbarung zur Übernahme von Eczacıbaşı-Monrol eine erhebliche Ausweitung der Lutetium-177-Kapazitäten und der Präsenz im PET-Bereich

Die geplante Übernahme von Eczacıbaşı-Monrol soll Folgendes erreichen: Ausbau der bestehenden Partnerschaft im Bereich Lu-177, um führender Hersteller des Isotops zu werdenErweiterung des bestehenden...
April 09, 2024 04:13 ET | Source: Curium US LLC

Curium prévoit d’augmenter considérablement sa capacité de production de lutécium-177 et son empreinte PET grâce à l’acquisition d’Eczacibaşi-Monrol

Le projet d’acquisition d’Eczacıbaşı-Monrol va : Tirer parti de l’actuel partenariat dans le domaine du Lu-177 pour donner naissance à un fabricant de premier plan de cet isotopeAjouter 12 sites...
April 08, 2024 03:25 ET | Source: Curium

Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol

CURIUM AGREEMENT TO ACQUIRE ECZACIBAŞI-MONROL
March 07, 2024 08:51 ET | Source: Curium

CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA

Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
March 07, 2024 08:51 ET | Source: Curium

Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer

PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
February 22, 2024 06:19 ET | Source: Curium

Curium Announces Submission of the Marketing Authorization Application for PYLCLARI®, an Innovative (18F)-PSMA PET Tracer Indicated in Adults With Prostate Cancer to Swissmedic

PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...